<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Biomedical Sciences</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9AD38C5D-18C2-4277-8CF7-97619F3B1B67"><gtr:id>9AD38C5D-18C2-4277-8CF7-97619F3B1B67</gtr:id><gtr:firstName>Sebastian</gtr:firstName><gtr:otherNames>Giles Becket</gtr:otherNames><gtr:surname>Amyes</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1706A13F-1E34-4895-9C75-02354A21C082"><gtr:id>1706A13F-1E34-4895-9C75-02354A21C082</gtr:id><gtr:firstName>Kevin</gtr:firstName><gtr:surname>Towner</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CF8FDA2D-A2A5-49C7-8B8E-A43ADED69EC0"><gtr:id>CF8FDA2D-A2A5-49C7-8B8E-A43ADED69EC0</gtr:id><gtr:firstName>Susan</gtr:firstName><gtr:surname>Brown</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0501433"><gtr:id>56998827-9D78-4EC8-8401-E3DF720E8075</gtr:id><gtr:title>Progression to pan-resistance in Acinetobacter baumannii: evolution and spread of OXA carbapenemase genes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501433</gtr:grantReference><gtr:abstractText>Antibiotics have been one of the fastest growth areas in pharmaceuticals since their clinical introduction 50 years ago. However, this apparent wealth of new drugs has masked the true reason for this explosion, simply the bacteria were becoming resistant to each drug as it was being introduced. We did not know how to use the antibiotics in a manner to prevent the emergence of resistance because we did not understand how resistance really develops within the clinical population. Carbapenems are the final major antibiotic group that can effectively treat infections caused by A. baumannii. This project aims to understand how carbapenem resistance caused by OXA beta-lactamases develops within A. baumannii, not just at the molecular level but also within a species. It aims to question the belief that resistant bacteria are simply sensitive bacteria that acquire resistance but rather they derive from sub-populations of bacteria selected during therapy. If we can determine how this resistance enters and spreads through the population, we shall be in a better position to control it.</gtr:abstractText><gtr:technicalSummary>Acinetobacter baumannii is a major Gram-negative pathogen responsible for hospital-acquired infection. Carbapenems are the final drug of choice but many strains are now carbapenem resistant; this is usually manifested by beta-lactamases of the OXA molecular class D. This project seeks to determine how widespread the OXA beta-lactamases are in strains of A. baumannii isolated from Europe and to establish where their genes are located, in particular on plasmids or within mobile genetic elements able to move between replicons. The environment within the strain may be crucial to the ability to transfer so this will be investigated both at the structural level and within strains that have altered capabilities to develop resistance. Closely related enzymes appear to have differing capabilities to confer carbapenem resistance so the activity of the enzymes will be carefully assayed and analysed then the results will be compared with the amino acid structure. The strains harbouring enzymes that have lesser capability to confer carbapenem resistance will be examined to understand why this is the case; whether structural differences are responsible or the enzyme is sufficiently repressed that it is unable to be expressed efficiently. This will be examined by applying selective pressure by challenge with weaker carbapenems to determine if derepression can change the resistance phenotype. At the end of this project, we should have a clearer idea how the new OXA beta-lactamases contribute to the maintenance and spread of carbapenem resistance in A. baumannii.</gtr:technicalSummary><gtr:fund><gtr:end>2009-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>290712</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Book</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>307B04D4-3F3C-41CE-9F32-85A378207339</gtr:id><gtr:impact>Book for the Oxford University Press

Interest from the OUP</gtr:impact><gtr:outcomeId>oLBgr7LkWyQ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>45 lectures to Health professionals</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>ADEA0E4E-EDEC-4E93-ABA9-E68FAAB730BB</gtr:id><gtr:impact>45 lectures to health professions throughout the United Kingdom and international.

Change of prescribing policy and identification of the impact that individual prescribing policies have had on the development of resistance</gtr:impact><gtr:outcomeId>43122C2BE0D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Book</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1C1BCA91-A077-49C5-AD38-B29FDC64B69E</gtr:id><gtr:impact>General book on the evolution of bacteria and their role in infection

Too early to identify.</gtr:impact><gtr:outcomeId>290C78FE147</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Book</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CA398D9C-F4D9-46EB-B7FF-2859B66425F4</gtr:id><gtr:impact>Book on Antibacterial Chemotherapy for Oxford University Press

Positive feedback</gtr:impact><gtr:outcomeId>8A56DFF88B8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ARHAP sub-committee on ESBLs and carbpanemases</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>ECEB96C9-60F7-4FDB-A5E4-840AC7A1FCB5</gtr:id><gtr:impact>This committee is to report to ARHAP on the impact of ESBLs and carbapenemases. This should affect usage of antibiotics and their testing.</gtr:impact><gtr:outcomeId>1B2C1EE384B</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Scottish Management of Antimicrobial Resistance Action Plan (ScotMARAP)</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>961BB2BD-0A2B-474A-BC44-D8F778C59BBE</gtr:id><gtr:impact>The results obtained in this study were discussed for the ScotMARAP committee, which provided guidelines for dealing with Antibiotic Resistance in Scotland.</gtr:impact><gtr:outcomeId>25A25411B1B</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B7023F76-C4CA-409F-9066-77035516E8B8</gtr:id><gtr:title>Acinetobacter baumannii: emergence of four strains with novel bla(OXA-51-like) genes in patients with diabetes mellitus.</gtr:title><gtr:parentPublicationTitle>Journal of chemotherapy (Florence, Italy)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e567f0cf4014e0aa2431d97fd8315496"><gtr:id>e567f0cf4014e0aa2431d97fd8315496</gtr:id><gtr:otherNames>Alsultan AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1120-009X</gtr:issn><gtr:outcomeId>CD0145A8459</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F7F7059-17FF-4905-9E4F-FA21DB1ED30A</gtr:id><gtr:title>Acinetobacter: an old friend, but a new enemy.</gtr:title><gtr:parentPublicationTitle>The Journal of hospital infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1e0f6b1549657a0bbe5e4caf07b168d"><gtr:id>b1e0f6b1549657a0bbe5e4caf07b168d</gtr:id><gtr:otherNames>Towner KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0195-6701</gtr:issn><gtr:outcomeId>83A05EAB9CD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A15FF18B-8060-4A92-9CB9-31BAEEE0BA40</gtr:id><gtr:title>Occurrence of OXA-107 and ISAba1 in carbapenem-resistant isolates of Acinetobacter baumannii from Croatia.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58ed698c6d4c69458abf87d52826e9fe"><gtr:id>58ed698c6d4c69458abf87d52826e9fe</gtr:id><gtr:otherNames>Goic-Barisic I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>2CFE1B32EB6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>733B314D-1190-4D39-B1AF-E2AF37D54AB8</gtr:id><gtr:title>Eleven novel OXA-51-like enzymes from clinical isolates of Acinetobacter baumannii.</gtr:title><gtr:parentPublicationTitle>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/258a82e0c37282f0e375704d53cd79f9"><gtr:id>258a82e0c37282f0e375704d53cd79f9</gtr:id><gtr:otherNames>Evans BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1198-743X</gtr:issn><gtr:outcomeId>7902B7F1FD9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA877C9F-7385-41B5-89D1-0D2DE26B7B1C</gtr:id><gtr:title>Gram-negative non-fermenting bacteria from food-producing animals are low risk for hospital-acquired infections.</gtr:title><gtr:parentPublicationTitle>Journal of chemotherapy (Florence, Italy)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b3a3338f69c0338e8dab39e90bdc4a3"><gtr:id>5b3a3338f69c0338e8dab39e90bdc4a3</gtr:id><gtr:otherNames>Hamouda A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1120-009X</gtr:issn><gtr:outcomeId>34FF9F1A5EF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5118CD21-E035-4EAD-B798-272A88E9850D</gtr:id><gtr:title>Therapeutic options for infections caused by Acinetobacter baumannii</gtr:title><gtr:parentPublicationTitle>Antibiotiques</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5eec9fd4b39a7e94ae68b2851dafa3f6"><gtr:id>5eec9fd4b39a7e94ae68b2851dafa3f6</gtr:id><gtr:otherNames>Towner K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>C0E77353131</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BC5F146-D312-42B0-BE28-F3767F87E6E7</gtr:id><gtr:title>Effect of frameshift mutagen acriflavine on control of resistance genes in Acinetobacter baumannii.</gtr:title><gtr:parentPublicationTitle>Journal of medical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/454fbf9f3fcd57334086b6515f570ac6"><gtr:id>454fbf9f3fcd57334086b6515f570ac6</gtr:id><gtr:otherNames>Lopes BS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-2615</gtr:issn><gtr:outcomeId>pm_14489_29_20965922</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98678DE9-2A85-4C08-958A-DD43F6CD2C5D</gtr:id><gtr:title>The resistance profile of Acinetobacter baumannii strains isolated from the Aberdeen Royal Infirmary.</gtr:title><gtr:parentPublicationTitle>International journal of antimicrobial agents</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/454fbf9f3fcd57334086b6515f570ac6"><gtr:id>454fbf9f3fcd57334086b6515f570ac6</gtr:id><gtr:otherNames>Lopes BS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0924-8579</gtr:issn><gtr:outcomeId>pm_14489_29_22325121</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F58AB240-248C-4672-BF9A-0E4FD96C8215</gtr:id><gtr:title>Best in class: a good principle for antibiotic usage to limit resistance development?</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71e564ac83549f2458fc9d4ef4ccb6e6"><gtr:id>71e564ac83549f2458fc9d4ef4ccb6e6</gtr:id><gtr:otherNames>Amyes SG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>971BD196681</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEE7965F-3EFB-41B1-9749-84DA65B85714</gtr:id><gtr:title>OXA-51-like beta-lactamases and their association with particular epidemic lineages of Acinetobacter baumannii.</gtr:title><gtr:parentPublicationTitle>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/258a82e0c37282f0e375704d53cd79f9"><gtr:id>258a82e0c37282f0e375704d53cd79f9</gtr:id><gtr:otherNames>Evans BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1198-743X</gtr:issn><gtr:outcomeId>31A34A98F22</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>848FA25C-A308-42B0-ACB8-3FEF95D60E33</gtr:id><gtr:title>Disruption of the blaOXA-51-like gene by ISAba16 and activation of the blaOXA-58 gene leading to carbapenem resistance in Acinetobacter baumannii Ab244.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/454fbf9f3fcd57334086b6515f570ac6"><gtr:id>454fbf9f3fcd57334086b6515f570ac6</gtr:id><gtr:otherNames>Lopes BS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_14489_29_21980071</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1ABE1E4D-00DE-42CA-82FF-CE7F703D1C5B</gtr:id><gtr:title>Distribution of intrinsic plasmid replicase genes and their association with carbapenem-hydrolyzing class D beta-lactamase genes in European clinical isolates of Acinetobacter baumannii.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1e0f6b1549657a0bbe5e4caf07b168d"><gtr:id>b1e0f6b1549657a0bbe5e4caf07b168d</gtr:id><gtr:otherNames>Towner KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_14489_29_21300832</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07E5D8C0-370F-4C00-99BE-BFF8C238F00D</gtr:id><gtr:title>OXA-type ?-lactamases in Acinetobacter baumannii: emerging from the shadow of the extended-spectrum ?-lactamases</gtr:title><gtr:parentPublicationTitle>Reviews in Medical Microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7121f374cc3943da519fa90981ead44b"><gtr:id>7121f374cc3943da519fa90981ead44b</gtr:id><gtr:otherNames>Evans B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>FD69E55633B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E875823C-873F-409A-AAE7-018D64EE6538</gtr:id><gtr:title>Genetic diversity of carbapenem-resistant isolates of Acinetobacter baumannii in Europe.</gtr:title><gtr:parentPublicationTitle>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1e0f6b1549657a0bbe5e4caf07b168d"><gtr:id>b1e0f6b1549657a0bbe5e4caf07b168d</gtr:id><gtr:otherNames>Towner KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1198-743X</gtr:issn><gtr:outcomeId>79ACC98A6FB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F83545E-55AB-4EE7-ACB6-B65823469142</gtr:id><gtr:title>High prevalence of unrelated multidrug-resistant Acinetobacter baumannii isolates in Pakistani military hospitals.</gtr:title><gtr:parentPublicationTitle>International journal of antimicrobial agents</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/258a82e0c37282f0e375704d53cd79f9"><gtr:id>258a82e0c37282f0e375704d53cd79f9</gtr:id><gtr:otherNames>Evans BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0924-8579</gtr:issn><gtr:outcomeId>pm_14489_29_21481570</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0ED0ED4C-0EAC-4000-8EC1-3BAB16B32078</gtr:id><gtr:title>Novel genetic context of multiple bla OXA-58 genes in Acinetobacter genospecies 3.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/258a82e0c37282f0e375704d53cd79f9"><gtr:id>258a82e0c37282f0e375704d53cd79f9</gtr:id><gtr:otherNames>Evans BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_14489_29_20542900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE9FA0A5-EF9D-4993-8C24-3D8963F69CF8</gtr:id><gtr:title>Characterization of epidemiologically unrelated Acinetobacter baumannii isolates from four continents by use of multilocus sequence typing, pulsed-field gel electrophoresis, and sequence-based typing of bla(OXA-51-like) genes.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b3a3338f69c0338e8dab39e90bdc4a3"><gtr:id>5b3a3338f69c0338e8dab39e90bdc4a3</gtr:id><gtr:otherNames>Hamouda A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>pm_14489_29_20421437</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501433</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>